1
|
Biffoni M, Grani G, Melcarne R, Geronzi V, Consorti F, Ruggieri GD, Galvano A, Razlighi MH, Iannuzzi E, Engel TD, Pace D, Di Gioia CRT, Boniardi M, Durante C, Giacomelli L. Drawing as a Way of Knowing: How a Mapping Model Assists Preoperative Evaluation of Patients with Thyroid Carcinoma. J Clin Med 2024; 13:1389. [PMID: 38592234 PMCID: PMC10931768 DOI: 10.3390/jcm13051389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Revised: 02/08/2024] [Accepted: 02/26/2024] [Indexed: 04/10/2024] Open
Abstract
Background: Effective pre-surgical planning is crucial for achieving successful outcomes in endocrine surgery: it is essential to provide patients with a personalized plan to minimize operative and postoperative risks. Methods: Preoperative lymph node (LN) mapping is a structured high-resolution ultrasonography examination performed in the presence of two endocrinologists and the operating surgeon before intervention to produce a reliable "anatomical guide". Our aim was to propose a preoperative complete model that is non-invasive, avoids overdiagnosis of thyroid microcarcinomas, and reduces medical expenses. Results: The use of 'preoperative echography mapping' has been shown to be successful, particularly in patients with suspected or confirmed neoplastic malignancy. Regarding prognosis, positive outcomes have been observed both post-surgery and in terms of recurrence rates. We collected data on parameters such as biological sex, age, BMI, and results from cytologic tests performed with needle aspiration, and examined whether these parameters predict tumor malignancy or aggressiveness, calculated using a multivariate analysis (MVA). Conclusions: A standard multidisciplinary approach for evaluating neck lymph nodes pre-operation has proven to be an improved diagnostic and preoperative tool.
Collapse
Affiliation(s)
- Marco Biffoni
- Department of General and Specialist Surgery, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (M.B.); (V.G.); (G.D.R.); (A.G.); (M.H.R.); (E.I.); (T.D.E.); (L.G.)
| | - Giorgio Grani
- Department of Translational and Precision Medicine, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (G.G.); (C.D.)
| | - Rossella Melcarne
- Department of Translational and Precision Medicine, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (G.G.); (C.D.)
| | - Valerio Geronzi
- Department of General and Specialist Surgery, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (M.B.); (V.G.); (G.D.R.); (A.G.); (M.H.R.); (E.I.); (T.D.E.); (L.G.)
| | - Fabrizio Consorti
- Department of General Surgery, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy;
| | - Giuseppe De Ruggieri
- Department of General and Specialist Surgery, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (M.B.); (V.G.); (G.D.R.); (A.G.); (M.H.R.); (E.I.); (T.D.E.); (L.G.)
| | - Alessia Galvano
- Department of General and Specialist Surgery, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (M.B.); (V.G.); (G.D.R.); (A.G.); (M.H.R.); (E.I.); (T.D.E.); (L.G.)
| | - Maryam Hosseinpour Razlighi
- Department of General and Specialist Surgery, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (M.B.); (V.G.); (G.D.R.); (A.G.); (M.H.R.); (E.I.); (T.D.E.); (L.G.)
| | - Eva Iannuzzi
- Department of General and Specialist Surgery, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (M.B.); (V.G.); (G.D.R.); (A.G.); (M.H.R.); (E.I.); (T.D.E.); (L.G.)
| | - Tal Deborah Engel
- Department of General and Specialist Surgery, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (M.B.); (V.G.); (G.D.R.); (A.G.); (M.H.R.); (E.I.); (T.D.E.); (L.G.)
| | - Daniela Pace
- Department of Endocrinology, Valmontone Hospital, 00038 Valmontone, Italy;
| | - Cira Rosaria Tiziana Di Gioia
- Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy;
| | - Marco Boniardi
- Endocrine Surgery Unit, Niguarda Hospital, 20162 Milan, Italy;
| | - Cosimo Durante
- Department of Translational and Precision Medicine, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (G.G.); (C.D.)
| | - Laura Giacomelli
- Department of General and Specialist Surgery, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy; (M.B.); (V.G.); (G.D.R.); (A.G.); (M.H.R.); (E.I.); (T.D.E.); (L.G.)
| |
Collapse
|
2
|
Incorvaia L, Badalamenti G, Novo G, Gori S, Cortesi L, Brando C, Cinieri S, Curigliano G, Ricciardi GR, Toss A, Chiari R, Berardi R, Ballatore Z, Bono M, Bazan Russo TD, Gristina V, Galvano A, Damerino G, Blasi L, Bazan V, Russo A. Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD). ESMO Open 2024; 9:102196. [PMID: 38118367 PMCID: PMC10837774 DOI: 10.1016/j.esmoop.2023.102196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/22/2023] Open
Abstract
BACKGROUND The BRCA proteins play a key role in the homologous recombination (HR) pathway. Beyond BRCA1/2, other genes are involved in the HR repair (HRR). Due to the prominent role in the cellular repair process, pathogenic or likely pathogenic variants (PV/LPVs) in HRR genes may cause inadequate DNA damage repair in cardiomyocytes. PATIENTS AND METHODS This was a multicenter, hospital-based, retrospective cohort study to investigate the heart toxicity from anthracycline-containing regimens (ACRs) in the adjuvant setting of breast cancer (BC) patients carrying germline BRCA PV/LPVs and no-BRCA HRR pathway genes. The left ventricular ejection fraction (LVEF) was assessed using cardiac ultrasound before starting ACR therapy and at subsequent time points according to clinical indications. RESULTS Five hundred and three BC patients were included in the study. We predefined three groups: (i) BRCA cohort; (ii) no-BRCA cohort; (iii) variant of uncertain significance (VUS)/wild-type (WT) cohort. When baseline (T0) and post-ACR (T1) LVEFs between the three cohorts were compared, pre-treatment LVEF values were not different (BRCA1/2 versus HRR-no-BRCA versus VUS/WT cohort). Notably, during monitoring (T1, median 3.4 months), patients carrying BRCA or HRR no-BRCA germline pathogenic or likely pathogenic variants showed a statistically significant reduction of LVEF compared to baseline (T0). To assess the relevance of HRR on the results, we included the analysis of the subgroup of 20 BC patients carrying PV/LPVs in other genes not involved in HRR, such as mismatch repair genes (MUTYH, PMS2, MSH6). Unlike HRR genes, no significant differences in T0-T1 were found in this subgroup of patients. CONCLUSION Our data suggest that deleterious variants in HRR genes, leading to impaired HR, could increase the sensitivity of cardiomyocytes to ACR in early BC patients. In this subgroup of patients, other measurements, such as the global longitudinal strain, and a more in-depth assessment of risk factors may be proposed in the future to optimize cardiovascular risk management and improve long-term survival.
Collapse
Affiliation(s)
- L Incorvaia
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo
| | - G Badalamenti
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo
| | - G Novo
- Division of Cardiology, University Hospital Paolo Giaccone, Palermo; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) "G. D'Alessandro", University of Palermo, Palermo
| | - S Gori
- Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella
| | - L Cortesi
- Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena
| | - C Brando
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo
| | - S Cinieri
- Complex Medical Oncology Unit, ASL Brindisi Senatore Antonio Perrino Hospital, Brindisi
| | - G Curigliano
- Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan
| | - G R Ricciardi
- Medical Oncology Unit, A.O. Papardo & Department of Human Pathology, University of Messina, Messina
| | - A Toss
- Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena
| | - R Chiari
- Medical Oncology, Ospedali Riuniti Padova Sud, Monselice
| | - R Berardi
- Medical Oncology, AOU Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Polytechnic University of the Marche Region, Ancona
| | - Z Ballatore
- Medical Oncology, AOU Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Polytechnic University of the Marche Region, Ancona
| | - M Bono
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo
| | - T D Bazan Russo
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo
| | - V Gristina
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo
| | - A Galvano
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo
| | - G Damerino
- Division of Cardiology, University Hospital Paolo Giaccone, Palermo
| | - L Blasi
- Medical Oncology Unit, ARNAS Civico, Palermo
| | - V Bazan
- Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bind), Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - A Russo
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo.
| |
Collapse
|
3
|
Badalamenti G, Algeri L, Dimino A, Magrin L, De Luca I, Sciacchitano R, Alimondi F, Gennusa V, Caiozzo I, Bazan Russo T, Galvano A, Gristina V, Bazan V, Incorvaia L, Russo A. 69P Trabectedin rechallenge for the treatment of adults with advanced soft tissue sarcoma (STS): A pilot study (Re-Trabe). ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.101106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
4
|
La Mantia M, De Monte L, Tancredi G, Giunta D, Ferrigno P, Gristina V, Galvano A, Barraco N, Rizzo S, Russo TB, Salemi D, Santoro A, Liotta R, Bertani A, Russo A, Bazan V. EP08.03-007 Spontaneous Regression in Metastatic Non-small Cell Lung Cancer: A Case Report. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
5
|
Gristina V, Barraco N, Galvano A, La Mantia M, Cutaia S, Iacono F, Lisanti C, Inguglia S, Sardo D, Perez A, Cusenza S, Castellana L, Bazan Russo T, Vieni S, Fulfaro F, Incorvaia L, Badalamenti G, Bazan V, Russo A. 1094P The clinical potential of circulating-free DNA (cfDNA) for real-time longitudinally monitoring clinical outcomes in a real-world first-line non-small cell lung cancer (NSCLC) prospective study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
6
|
La Mantia M, Gristina V, Galvano A, Barraco N, Perez A, Cutaia S, Sardo D, Inguglia S, Busuito G, Spinnato V, Iacono F, Insalaco L, Castellana L, Calò V, cusenza S, Fulfaro F, Incorvaia L, Badalamenti G, Russo TB, Vieni S, Russo A, Bazan V. EP16.01-013 The Diagnostic Accuracy of Tumor Mutational Burden in Advanced NSCLC: An Individual Patient Data Meta-Analysis. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
7
|
Incorvaia L, Fiorino A, Gori S, Cinieri S, Curigliano G, Toss A, Cortesi L, Ricciardi G, Chiari R, Peri M, Brando C, Bazan Russo T, Gristina V, Galvano A, Damerino G, Carreca I, Novo G, Badalamenti G, Bazan V, Russo A. 904MO Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
8
|
Peri M, Incorvaia L, Spinnato V, Corsini L, Scalia R, Dimino A, Algeri L, Schiacchitano R, Magrin L, Galvano A, Gristina V, Cusenza S, Bazan V, Badalamenti G, Russo A. P-173 Understanding the treatment algorithm of patients with advanced G2 gastroenteropancreatic neuroendocrine neoplasms: A single-institution retrospective analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
9
|
Incorvaia L, Brando C, Algeri L, Dimino A, Pedone E, Schiacchitano R, Magrin L, Fiorino A, Perez A, Barraco N, Bono M, Cancelliere D, Pivetti A, Bazan Russo T, Contino S, Gristina V, Galvano A, Bazan V, Russo A, Badalamenti G. P-264 The molecular-metabolic interplay in metastatic gastrointestinal stromal tumors (GISTs): The predictive role of body mass index. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
10
|
Bilello G, Fazio M, Amato E, Crivello L, Galvano A, Currò G. Accuracy evaluation of orthodontic movements with aligners: a prospective observational study. Prog Orthod 2022; 23:12. [PMID: 35399128 PMCID: PMC8995220 DOI: 10.1186/s40510-022-00406-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Accepted: 03/27/2022] [Indexed: 11/28/2022] Open
Abstract
Background Since their introduction in orthodontics, clear aligners have been appreciated by patients, including adults, for their comfort and low aesthetic impact. Despite the enormous mobilization of financial resources all over the world aimed at producing new product lines, few clinical studies or high-quality evidence have been produced regarding the real effectiveness of such treatment. Given the few limited kinds of research on the subject, this study aims to produce and critically evaluate other data, to establish the concrete reliability of clear aligners in orthodontic therapy. Results Significant sample sizes were obtained for intrusion, vestibulo/lingual (V/L) crown tipping, and rotation. The overall accuracy for rotation resulted in 86%, ranging from 96% for maxillary central incisors to 70.4% for mandibular first premolars. The intrusion was registered only for anterior teeth; mean predictability was 92%, with the worst result being 86.7% for mandibular canines and the best being 98% for mandibular central incisors. V/L tipping was the most accurate movement: 93.1% of the prescribed movement was completed. Maxillary central incisors showed the lowest accuracy (80.7%), while mandibular central incisors were the highest (97.5%). Conclusions The present study provided reassuring data in support of the accuracy of the Invisalign® system. Vestibulo/lingual tipping was the most predictable movement, while rotation of canines, premolars, and lateral incisors were the least predictable. Intrusion resulted highly predictable up to 2 mm. When careful treatment planning follows a correct diagnosis, together with the use of auxiliary features and refinements, the planned results can be achieved in a clinically successful way. Authors believe that there is a major need for greater samples to overcome bias related to variables if we want to answer the unsolved questions, such as the predictability of severe malocclusions treatment.
Collapse
|
11
|
Badalamenti G, Incorvaia L, Bonasera A, Algeri L, Dimino A, Cucinella A, Madonia G, Scalia R, Fanale D, Li Pomi F, Galvano A, Gristina V, Corsini L, Brando C, Bazan V, Russo A. 1543P Gemcitabine in classic Kaposi’s sarcoma: A pilot study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Gristina V, Galvano A, Mirisola M, La Mantia M, Giaconia M, Li Pomi F, Barraco N, Castiglia M, Perez A, Bono M, Iacono F, Cutaia S, Lisanti M, Insalaco L, Castellana L, Calò V, Cusenza S, Incorvaia L, Russo A, Bazan V. 1818P Body mass index (BMI) is not a cancer risk factor for BRCA1/2 carriers: A systematic review and meta-analysis of case-control studies. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
13
|
Galvano A, Gristina V, Malapelle U, Pisapia P, Pepe F, Barraco N, Castiglia M, Perez A, Rolfo C, Troncone G, Russo A, Bazan V. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. ESMO Open 2021; 6:100124. [PMID: 33940346 PMCID: PMC8111593 DOI: 10.1016/j.esmoop.2021.100124] [Citation(s) in RCA: 61] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Revised: 01/30/2021] [Accepted: 04/01/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND The role of tumor mutational burden (TMB) is still debated for selecting advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might benefit from immune checkpoint inhibitors (ICIs). Of note, TMB failed to predict a benefit in overall survival (OS) among such patients. MATERIALS AND METHODS The purpose of this meta-analysis was to compare efficacy outcomes among first-line immune-oncology (IO) agents versus standard platinum-based chemotherapy (CT) within two subgroups (TMB-low and TMB-high on either tissue or blood). We collected hazard ratios (HRs) to evaluate the association for progression-free survival (PFS) and OS, with the relative 95% confidence intervals (CIs). Risk ratios (RRs) were used as an association measure for objective response rate (ORR). RESULTS Eight different cohorts of five randomized controlled phase III studies (3848 patients) were analyzed. In TMB-high patients, IO agents were associated with improved ORR (RRs 1.37, 95% CI 1.13-1.66), PFS (HR 0.69, 95% CI 0.61-0.79) and OS (HR 0.67, 95% CI 0.59-0.77) when compared with CT, thus suggesting a possible predictive role of high TMB for IO regimens. In TMB-low patients, the IO strategy did not lead to any significant benefit in survival and activity, whereas the pooled results of both ORR and PFS were intriguingly associated with a statistical significance in favor of CT. CONCLUSIONS This meta-analysis resulted in a proven benefit in OS in favor of IO agents in the TMB-high population. Although more prospective data are warranted, we postulated the hypothesis that monitoring TMB, in addition to the existing programmed death-ligand 1 (PD-L1) expression level, could represent the preferable option for future clinical research in the first-line management of advanced non-oncogene addicted NSCLC patients.
Collapse
Affiliation(s)
- A Galvano
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - V Gristina
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - U Malapelle
- Department of Public Health, University Federico II of Naples, Naples, Italy
| | - P Pisapia
- Department of Public Health, University Federico II of Naples, Naples, Italy
| | - F Pepe
- Department of Public Health, University Federico II of Naples, Naples, Italy
| | - N Barraco
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - M Castiglia
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - A Perez
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - C Rolfo
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, USA
| | - G Troncone
- Department of Public Health, University Federico II of Naples, Naples, Italy
| | - A Russo
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
| | - V Bazan
- Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo, Italy
| |
Collapse
|
14
|
Gristina V, Galvano A, Castiglia M, Perez A, Barraco N, Castellana L, Insalaco L, Peri M, Iacono F, Cucinella A, Bono M, Cusenza S, Rizzo S, Bazan V, Russo A. P33.15 TMB in the First-Line Setting of NSCLC: A Systematic Review with Indirect Comparisons Between PD-1 and PD-L1 Inhibitors. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Galvano A, Gristina V, Barraco N, Perez A, Castiglia M, La Mantia M, Cutaia S, Iacono F, Castellana L, Insalaco L, Bono M, Peri M, Madonia G, Cusenza S, Rizzo S, Bazan V, Russo A. P48.10 Chemo-Immunotherapy in the Frontline of Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Indirect Comparisons. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Passiglia F, Galvano A, Soto Parra H, Rizzo S, Listì A, Mazzarisi S, Perez A, Castiglia M, Calò V, Bazan V, Russo A. P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
17
|
Vincenzi B, Russo A, Terenzio A, Galvano A, Santini D, Vorini F, Antonelli-Incalzi R, Vespasiani-Gentilucci U, Tonini G. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol 2018; 130:70-77. [PMID: 30196914 DOI: 10.1016/j.critrevonc.2018.06.019] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2018] [Revised: 06/22/2018] [Accepted: 06/25/2018] [Indexed: 02/07/2023] Open
Abstract
Drug-induced liver injury (DILI) remains the most common cause of acute liver failure in the Western world. Chemotherapy is one of the major class of drugs most frequently associated with idiosyncratic DILI. For this reason, patients who receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate and which drug doses should be modified. S-adenosylmethionine (SAMe) is an endogenous agent derived from methionine. Its supplementation is effective in the treatment of liver disease, in particular intrahepatic cholestasis (IHC). The target of this review is to analyze the mechanisms of hepatotoxicity of the principal anticancer agents and the role of SAMe in the prevention of this complication.
Collapse
Affiliation(s)
- B Vincenzi
- Medical Oncology Unit, Campus Bio-Medico University, Rome, Italy.
| | - A Russo
- Department of Surgery and Oncology, Section of Medical Oncology, University of Palermo, Italy
| | - A Terenzio
- Medical Oncology Unit, Campus Bio-Medico University, Rome, Italy
| | - A Galvano
- Department of Surgery and Oncology, Section of Medical Oncology, University of Palermo, Italy
| | - D Santini
- Medical Oncology Unit, Campus Bio-Medico University, Rome, Italy
| | - F Vorini
- Interdisciplinary Center for Biomedical Research (CIR), Laboratory of Internal Medicine and Hepatology, Campus Bio-Medico University, Rome, Italy
| | | | - U Vespasiani-Gentilucci
- Interdisciplinary Center for Biomedical Research (CIR), Laboratory of Internal Medicine and Hepatology, Campus Bio-Medico University, Rome, Italy
| | - G Tonini
- Medical Oncology Unit, Campus Bio-Medico University, Rome, Italy
| |
Collapse
|
18
|
Maragliano R, Fanale D, Incorvaia L, Caruso S, Barraco N, Badalamenti G, Rizzo S, Calò V, Perez A, Listì A, Galvano A, Passiglia F, Guarini A, Bronte E, Insalaco L, Massihnia D, Castellana L, Di Piazza F, Bazan V, Russo A. Can the salivary microRNA expression profile help to identify novel biomarkers for oral squamous cell carcinoma detection? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx430.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Fanale D, Incorvaia L, Maragliano R, Barraco N, Listì A, Galvano A, Rizzo S, Calò V, Corsini L, Bazan V, Russo A. Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Massihnia D, Funel N, Leon L, Castiglia M, Perez A, Barraco N, Listì A, Galvano A, Passiglia F, Guarini A, Calò V, Rizzo S, Castellana L, Giovannetti E, Russo A. Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Fanale D, Incorvaia L, Maragliano R, Barraco N, Listì A, Galvano A, Rizzo S, Calò V, Bazan V, Russo A. Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx361.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Incorvaia L, Badalamenti G, Musso E, de luca I, Casarin A, Assanto G, Galvano A, Passiglia F, Barraco N, Vincenzi B, Grignani G, Pantaleo M, Gatto L, Rizzo S, Fanale D, Castiglia M, Guarini A, Russo A. Predictive factors of response to Sunitinib in metastatic Gastrointestinal Stromal Tumors (mGISTs): A retrospective analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Barraco N, Incorvaia L, Badalamenti G, Passiglia F, Listì A, Maragliano R, Musso E, Bronte E, Cabibi D, Calò V, Castiglia M, Fanale D, Galvano A, Gristina V, Ingrao S, Insalaco L, Massihnia D, Perez A, Bazan V, Russo A. LncRNA H19, HOTAIR and MALAT1 as prognostic molecular biomarkers in GIST. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
24
|
Passiglia F, Listì A, Barraco N, Galvano A, Fanale D, Incorvaia L, Bazan V, Rolfo C, Russo A. Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: A pooled analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx094.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
25
|
Passiglia F, Galvano A, Rizzo S, Listì A, Barraco N, Maragliano R, Insalaco L, Bronte E, Alessi I, Guarini A, Terruso L, Castellana L, Perez A, Massihnia D, Di Piazza F, Calò V, Castiglia M, Bazan V, Russo A. The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Abstract
The inhibition of the mechanisms of tumor neo-angiogenesis represents a milestone that in the last 10 years has seen the advent of numerous molecules to target action against the vascular endothelial growth factor (VEGF). More recently, new molecules have been developed that inhibit tumor spread by the blockade of specific VEGF receptors (VEGFRs), thereby preventing the binding of a ligand to its receptor and the cascade of proliferative events downstream. Ramucirumab is a fully humanized IgG1 monoclonal antibody that performs its action by blocking the isoform 2 of the VEGF receptor (VEGFR-2). Numerous preclinical and clinical studies have demonstrated its activity in several solid tumors, demonstrating a remarkable efficacy in terms of progression-free survival and overall survival in addition to a favorable toxicity profile. This review analyzes in detail the role of ramucirumab in the treatment of advanced gastric and gastroesophageal junction cancers.
Collapse
Affiliation(s)
- G Bronte
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - A Galvano
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - G Cicero
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - F Passiglia
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - C Rolfo
- Phase I Unit-Early Clinical Trials, University of Antwerp, Edegem, Belgium
| | - V Bazan
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - A Russo
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
| |
Collapse
|
27
|
Badalamenti G, Bronte G, Provenzano S, Galvano A, Piazza D, Bartolotta S, Maltese G, Albanese V, Catania G, Gianfortuna G, Incorvaia L, Rizzo S, Russo A. 69 PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA BY LENOGRASTIM IN SARCOMA, BREAST AND LUNG CANCER PATIENTS TREATED WITH CHEMOTHERAPY. Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70095-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Affiliation(s)
- N J Zeiguer
- Department of Gynecology, Municipal Hospital Juan A. Fernandez, Buenos Aires, Argentina
| | | | | | | | | |
Collapse
|